Cargando…
Incomplete response in late-life depression: getting to remission
Incomplete response in the treatmen tof late-life depression is a large public health challenge: at least 50% of older people fail to respond adequately to first-line antidepressant pharmacotherapy, even under optimal treatment conditions. Treatment-resistant late-life depression (TRLLD) increases r...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181898/ https://www.ncbi.nlm.nih.gov/pubmed/19170399 |
_version_ | 1782212836628365312 |
---|---|
author | Lenze, Eric J. Sheffrin, Meera Driscoll, Henry C Mulsant, Benoit H. Pollock, Bruce G. Amanda Dew, Mary Lotrich, Frank Devlin, Bernie Bies, Robert Reynolds III, Charles F. |
author_facet | Lenze, Eric J. Sheffrin, Meera Driscoll, Henry C Mulsant, Benoit H. Pollock, Bruce G. Amanda Dew, Mary Lotrich, Frank Devlin, Bernie Bies, Robert Reynolds III, Charles F. |
author_sort | Lenze, Eric J. |
collection | PubMed |
description | Incomplete response in the treatmen tof late-life depression is a large public health challenge: at least 50% of older people fail to respond adequately to first-line antidepressant pharmacotherapy, even under optimal treatment conditions. Treatment-resistant late-life depression (TRLLD) increases risk for early relapse, undermines adherence to treatment for coexisting medical disorders, amplifies disability and cognitive impairment, imposes greater burden on family caregivers, and increases the risk for early mortality, including suicide, Gettinq to and sustaininq remission is the primary goal of treatment yet there is a paucity of empirical data on how best to manage TRLLD. A pilot study by our group on aripiprazole augmentation in 24 incomplete responders to sequential SSRI and SRNI pharmacotherapy found that 50% remitted over 12 weeks with the addition of aripiprazole, and that remission was sustained in all participants during 6 months of continuation treatment In addition to controlled assessment, evidence is needed to support personalized treatment by testing the moderating role of clinical (eg, comorbid anxiety, medical burden, and executive impairment) and genetic (eg, selected polymorphisms in serotonin, norepinephrine, and dopamine genes) variables, while also controlling for variability in drug exposure. Such studies may advance us toward the goal of personalized treatment in late-life depression. |
format | Online Article Text |
id | pubmed-3181898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-31818982011-10-27 Incomplete response in late-life depression: getting to remission Lenze, Eric J. Sheffrin, Meera Driscoll, Henry C Mulsant, Benoit H. Pollock, Bruce G. Amanda Dew, Mary Lotrich, Frank Devlin, Bernie Bies, Robert Reynolds III, Charles F. Dialogues Clin Neurosci Translational Research Incomplete response in the treatmen tof late-life depression is a large public health challenge: at least 50% of older people fail to respond adequately to first-line antidepressant pharmacotherapy, even under optimal treatment conditions. Treatment-resistant late-life depression (TRLLD) increases risk for early relapse, undermines adherence to treatment for coexisting medical disorders, amplifies disability and cognitive impairment, imposes greater burden on family caregivers, and increases the risk for early mortality, including suicide, Gettinq to and sustaininq remission is the primary goal of treatment yet there is a paucity of empirical data on how best to manage TRLLD. A pilot study by our group on aripiprazole augmentation in 24 incomplete responders to sequential SSRI and SRNI pharmacotherapy found that 50% remitted over 12 weeks with the addition of aripiprazole, and that remission was sustained in all participants during 6 months of continuation treatment In addition to controlled assessment, evidence is needed to support personalized treatment by testing the moderating role of clinical (eg, comorbid anxiety, medical burden, and executive impairment) and genetic (eg, selected polymorphisms in serotonin, norepinephrine, and dopamine genes) variables, while also controlling for variability in drug exposure. Such studies may advance us toward the goal of personalized treatment in late-life depression. Les Laboratoires Servier 2008-12 /pmc/articles/PMC3181898/ /pubmed/19170399 Text en Copyright: © 2008 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Translational Research Lenze, Eric J. Sheffrin, Meera Driscoll, Henry C Mulsant, Benoit H. Pollock, Bruce G. Amanda Dew, Mary Lotrich, Frank Devlin, Bernie Bies, Robert Reynolds III, Charles F. Incomplete response in late-life depression: getting to remission |
title | Incomplete response in late-life depression: getting to remission |
title_full | Incomplete response in late-life depression: getting to remission |
title_fullStr | Incomplete response in late-life depression: getting to remission |
title_full_unstemmed | Incomplete response in late-life depression: getting to remission |
title_short | Incomplete response in late-life depression: getting to remission |
title_sort | incomplete response in late-life depression: getting to remission |
topic | Translational Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181898/ https://www.ncbi.nlm.nih.gov/pubmed/19170399 |
work_keys_str_mv | AT lenzeericj incompleteresponseinlatelifedepressiongettingtoremission AT sheffrinmeera incompleteresponseinlatelifedepressiongettingtoremission AT driscollhenryc incompleteresponseinlatelifedepressiongettingtoremission AT mulsantbenoith incompleteresponseinlatelifedepressiongettingtoremission AT pollockbruceg incompleteresponseinlatelifedepressiongettingtoremission AT amandadewmary incompleteresponseinlatelifedepressiongettingtoremission AT lotrichfrank incompleteresponseinlatelifedepressiongettingtoremission AT devlinbernie incompleteresponseinlatelifedepressiongettingtoremission AT biesrobert incompleteresponseinlatelifedepressiongettingtoremission AT reynoldsiiicharlesf incompleteresponseinlatelifedepressiongettingtoremission |